Ontogeny of circulating lipid metabolism in pregnancy and early childhood: a longitudinal population study

  1. Satvika Burugupalli
  2. Adam Alexander T Smith
  3. Gavriel Oshlensky
  4. Kevin Huynh
  5. Corey Giles
  6. Tingting Wang
  7. Alexandra George
  8. Sudip Paul
  9. Anh Nguyen
  10. Thy Duong
  11. Natalie Mellett
  12. Michelle Cinel
  13. Sartaj Ahmad Mir
  14. Li Chen
  15. Markus R Wenk
  16. Neerja Karnani
  17. Fiona Collier
  18. Richard Saffery
  19. Peter Vuillermin
  20. Anne-Louise Ponsonby
  21. David Burgner  Is a corresponding author
  22. Peter Meikle  Is a corresponding author
  1. Baker Heart and Diabetes Institute, Australia
  2. National University of Singapore, Singapore
  3. Singapore Institute for Clinical Sciences, A*STAR, Singapore
  4. Deakin University, Australia
  5. Murdoch Children's Research Institute, Australia
  6. The Florey Institute of Neuroscience and Mental Health, Australia
  7. Murdoch Children's Research Institute, Australia

Abstract

Background: There is mounting evidence that in utero and early life exposures may predispose an individual to metabolic disorders in later life; and dysregulation of lipid metabolism is critical in such outcomes. However, there is limited knowledge about lipid metabolism and factors causing lipid dysregulation in early life that could result in adverse health outcomes in later life. We studied the effect of antenatal factors such as gestational age, birth weight and mode of birth on lipid metabolism at birth; changes in the circulating lipidome in the first four years of life and the effect of breastfeeding in the first year of life. From this study, we aim to generate a framework for deeper understanding into factors effecting lipid metabolism in early life, to provide early interventions for those at risk of developing metabolic disorders including cardiovascular diseases.

Methods and findings: We performed comprehensive lipid profiling of 1074 mother-child dyads in the Barwon Infant Study (BIS), a population based pre-birth cohort and measured 776 distinct lipid species across 42 lipid classes using ultra high-performance liquid chromatography (UHPLC). We measured lipids in 1032 maternal serum samples at 28 weeks' gestation, 893 cord serum samples at birth, 793, 735, and 511 plasma samples at six, twelve months, and four years, respectively. The lipidome differed between mother and newborn and changed markedly with increasing child's age. Cord serum was enriched with long chain poly-unsaturated fatty acids (LC-PUFAs), and corresponding cholesteryl esters relative to the maternal serum. Alkenylphosphatidylethanolamine species containing LC-PUFAs increased with child's age, whereas the corresponding lysophospholipids and triglycerides decreased. We performed regression analyses to investigate the associations of cord serum lipid species with antenatal factors: gestational age, birth weight, mode of birth and duration of labor. Majority of the cord serum lipids were strongly associated with gestational age and birth weight, with most lipids showing opposing associations. Each mode of birth showed an independent association with cord serum lipids. Breastfeeding had a significant impact on the plasma lipidome in the first year of life, with upto 17-fold increases in a few species of alkyldiaclylglycerols at 6 months of age.

Conclusions: This study sheds light on lipid metabolism in infancy and early childhood and provide a framework to define the relationship between lipid metabolism and health outcomes in early childhood.

Funding Statement: This work was supported by the A*STAR-NHMRC joint call funding (1711624031).

Data availability

Due to the consent obtained during recruitment process, it is not possible to make all data publicly available. Access to BIS data including all data used in this paper may be requested through the BIS Steering Committee by contacting the corresponding author. Requests to access cohort data are considered on scientific and ethical grounds and, if approved, provided under collaborative research agreements. Deidentified cohort data can be provided in Stata or CSV format. All statistical methods used are referenced within the methods section. Data that is not subject to data-sharing restrictions can be found in Supplementary File 1. Additional project information, including cohort data description and access procedures, is available at the project's website https://www.barwoninfantstudy.org.au

Article and author information

Author details

  1. Satvika Burugupalli

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  2. Adam Alexander T Smith

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  3. Gavriel Oshlensky

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  4. Kevin Huynh

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Corey Giles

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourn, Australia
    Competing interests
    The authors declare that no competing interests exist.
  6. Tingting Wang

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  7. Alexandra George

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  8. Sudip Paul

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  9. Anh Nguyen

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  10. Thy Duong

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  11. Natalie Mellett

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  12. Michelle Cinel

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  13. Sartaj Ahmad Mir

    Department of Biochemistry, National University of Singapore, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  14. Li Chen

    Singapore Institute for Clinical Sciences, A*STAR, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  15. Markus R Wenk

    Department of Biochemistry, National University of Singapore, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  16. Neerja Karnani

    Singapore Institute for Clinical Sciences, A*STAR, Singapore, Singapore
    Competing interests
    The authors declare that no competing interests exist.
  17. Fiona Collier

    School of Medicine, Deakin University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5438-480X
  18. Richard Saffery

    Murdoch Children's Research Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  19. Peter Vuillermin

    School of Medicine, Deakin University, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  20. Anne-Louise Ponsonby

    The Florey Institute of Neuroscience and Mental Health, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6581-3657
  21. David Burgner

    Infection and Immunity, Murdoch Children's Research Institute, Parkville, Australia
    For correspondence
    david.burgner@mcri.edu.au
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8304-4302
  22. Peter Meikle

    Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia
    For correspondence
    peter.meikle@baker.edu.au
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2593-4665

Funding

National Health and Medical Research Council (A*STAR-NHMRC joint call funding (1711624031).)

  • Peter Meikle

National Health and Medical Research Council (A*STAR-NHMRC joint call funding (1711624031).)

  • Markus R Wenk
  • Neerja Karnani
  • Fiona Collier
  • Richard Saffery
  • Peter Vuillermin
  • Anne-Louise Ponsonby
  • David Burgner

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Hossein Ardehali, Northwestern University, United States

Ethics

Human subjects: The original study was granted by the Barwon Health Human Research and Ethics Committee (HREC 10/24).

Version history

  1. Received: August 4, 2021
  2. Preprint posted: September 22, 2021 (view preprint)
  3. Accepted: February 24, 2022
  4. Accepted Manuscript published: March 2, 2022 (version 1)
  5. Version of Record published: March 23, 2022 (version 2)

Copyright

© 2022, Burugupalli et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,331
    views
  • 212
    downloads
  • 9
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Satvika Burugupalli
  2. Adam Alexander T Smith
  3. Gavriel Oshlensky
  4. Kevin Huynh
  5. Corey Giles
  6. Tingting Wang
  7. Alexandra George
  8. Sudip Paul
  9. Anh Nguyen
  10. Thy Duong
  11. Natalie Mellett
  12. Michelle Cinel
  13. Sartaj Ahmad Mir
  14. Li Chen
  15. Markus R Wenk
  16. Neerja Karnani
  17. Fiona Collier
  18. Richard Saffery
  19. Peter Vuillermin
  20. Anne-Louise Ponsonby
  21. David Burgner
  22. Peter Meikle
(2022)
Ontogeny of circulating lipid metabolism in pregnancy and early childhood: a longitudinal population study
eLife 11:e72779.
https://doi.org/10.7554/eLife.72779

Share this article

https://doi.org/10.7554/eLife.72779

Further reading

    1. Epidemiology and Global Health
    Yuchen Zhang, Yitang Sun ... Kaixiong Ye
    Research Article

    Background:

    Circulating omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) have been associated with various chronic diseases and mortality, but results are conflicting. Few studies examined the role of omega-6/omega-3 ratio in mortality.

    Methods:

    We investigated plasma omega-3 and omega-6 PUFAs and their ratio in relation to all-cause and cause-specific mortality in a large prospective cohort, the UK Biobank. Of 85,425 participants who had complete information on circulating PUFAs, 6461 died during follow-up, including 2794 from cancer and 1668 from cardiovascular disease (CVD). Associations were estimated by multivariable Cox proportional hazards regression with adjustment for relevant risk factors.

    Results:

    Risk for all three mortality outcomes increased as the ratio of omega-6/omega-3 PUFAs increased (all Ptrend <0.05). Comparing the highest to the lowest quintiles, individuals had 26% (95% CI, 15–38%) higher total mortality, 14% (95% CI, 0–31%) higher cancer mortality, and 31% (95% CI, 10–55%) higher CVD mortality. Moreover, omega-3 and omega-6 PUFAs in plasma were all inversely associated with all-cause, cancer, and CVD mortality, with omega-3 showing stronger effects.

    Conclusions:

    Using a population-based cohort in UK Biobank, our study revealed a strong association between the ratio of circulating omega-6/omega-3 PUFAs and the risk of all-cause, cancer, and CVD mortality.

    Funding:

    Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under the award number R35GM143060 (KY). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

    1. Ecology
    2. Epidemiology and Global Health
    Aleksandra Kovacevic, David RM Smith ... Lulla Opatowski
    Research Article

    Non-pharmaceutical interventions implemented to block SARS-CoV-2 transmission in early 2020 led to global reductions in the incidence of invasive pneumococcal disease (IPD). By contrast, most European countries reported an increase in antibiotic resistance among invasive Streptococcus pneumoniae isolates from 2019 to 2020, while an increasing number of studies reported stable pneumococcal carriage prevalence over the same period. To disentangle the impacts of the COVID-19 pandemic on pneumococcal epidemiology in the community setting, we propose a mathematical model formalizing simultaneous transmission of SARS-CoV-2 and antibiotic-sensitive and -resistant strains of S. pneumoniae. To test hypotheses underlying these trends five mechanisms were built into the model and examined: (1) a population-wide reduction of antibiotic prescriptions in the community, (2) lockdown effect on pneumococcal transmission, (3) a reduced risk of developing an IPD due to the absence of common respiratory viruses, (4) community azithromycin use in COVID-19 infected individuals, (5) and a longer carriage duration of antibiotic-resistant pneumococcal strains. Among 31 possible pandemic scenarios involving mechanisms individually or in combination, model simulations surprisingly identified only two scenarios that reproduced the reported trends in the general population. They included factors (1), (3), and (4). These scenarios replicated a nearly 50% reduction in annual IPD, and an increase in antibiotic resistance from 20% to 22%, all while maintaining a relatively stable pneumococcal carriage. Exploring further, higher SARS-CoV-2 R0 values and synergistic within-host virus-bacteria interaction mechanisms could have additionally contributed to the observed antibiotic resistance increase. Our work demonstrates the utility of the mathematical modeling approach in unraveling the complex effects of the COVID-19 pandemic responses on AMR dynamics.